Iain Armstrong (Partner, HGF), Peter Scott (Editor-in-Chief, LSIPR)
Immunotherapies, such as CAR-T cells, are a hugely promising therapeutic area, both in terms of clinical benefits and potential market size.
While the treatments are complicated and expensive, they have proven remarkably effective in achieving positive outcomes in forms of cancer that are otherwise difficult to treat. As a result, their clinical use has recently been approved in both the US and Europe.
The webinar will consider how commercial and technological developments have also impacted patent filings in this area. As the field becomes increasingly crowded, the likelihood of obtaining very broad patent protection decreases. However, the number of patent filings continues to grow dramatically.